Alteration of caspase-3 (CPP32/Yama/apopain) in wild-type MCF-7, breast cancer cells

Oncology Reports

Volumn 6, Issue 1, 1999, Pages 33-37

  Kurokawa, Hirokazu ^a   Nishio, Kazuto ^a   Fukumoto, Hisao ^a   Tomonari, Akira ^a   Suzuki, Toshihiro ^a   Saijo, Nagahiro ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Apopcosis; Breast carcinoma; Caspase 3; CPP32

Indexed keywords

CASP3 PROTEIN, HUMAN; CASPASE; CASPASE 3; ESTROGEN; MESSENGER RNA; RNA; TUMOR NECROSIS FACTOR ALPHA; TUMOR PROTEIN;

ADENOCARCINOMA; AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; BREAST TUMOR; CELL CULTURE; DRUG EFFECT; ENZYMOLOGY; FEMALE; FRAMESHIFT MUTATION; GENE DELETION; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; NEOPLASM; NORTHERN BLOTTING; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SPLICING; SOUTHERN BLOTTING;

ADENOCARCINOMA; AMINO ACID SEQUENCE; APOPTOSIS; BASE SEQUENCE; BLOTTING, NORTHERN; BLOTTING, SOUTHERN; BREAST NEOPLASMS; CASPASE 3; CASPASES; ESTROGENS; FEMALE; FRAMESHIFT MUTATION; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA SPLICING; RNA, MESSENGER; RNA, NEOPLASM; SEQUENCE DELETION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032607858     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.6.1.33     Document Type: Article

References (20)

1. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, et al: Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376: 37-43, 1995.
2. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GO, Salvesen GS and Dixit VM: Yama/ CPP32ß, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81: 801-809, 1995.
3. Antoku K, Liu Z and Johnson DE: Inhibition of caspase proteases by CrmA enhances the resistance of human leukemic cells to multiple chemotherapeutic agents. Leukemia 11: 1665-1672, 1997.
4. Ibrado AM, Huang Y, Fang G and Bhalla K: Bcl-xL overexpression inhibits taxol-induced Yama protease activity and apoptosis. Cell Growth Differ 7: 1087-1094, 1996.
5. Medina V, Edmonds B, Young GP, James R, Appleton S and Zalewski PD: Induction of caspase-3 protease activity and apoptosis by butyrate and trichostatin A (inhibitors of histone deacetylase): dependence on protein synthesis and synergy with a mitochondrial/cytochrome c-dependent pathway. Cancer Res 57: 3697-3707, 1997.
6. Fuchs EJ, McKenna KA and Bedi A: p53-dependent DNA damage-induced apoptosis requires Fas/APO-1-independent activation of CPP32B. Cancer Res 57: 2550-2554, 1997.
7. Srinivasan A, Li F, Wong A, Kodandapani L, Smidt S Jr, Krebs JF, Fritz LC, Wu JC and Tomaselli KJ: Bcl-xL functions downstream of caspase-8 to inhibit Fas- and tumor necrosis factor receptor 1-induced apoptosis of MCF-7 breast carcinoma cells. J Biol Chem 273: 4523-4529, 1998.
8. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin K-M, Krammer PH and Peter ME: Two CD95 (APO-1/ Fas) signaling pathways. EMBO J 17: 1675-1687, 1998.
9. Suzuki T, Nishio K, Sasaki H, Kurokawa H, Saito-Ohara F, Ikeuchi T, Tanabe S, Terada M and Saijo N: cDNA cloning of a short type of multidrug resistance protein homologue, SMRP. from a human lung cancer cell line. Biochem Biophys Res Commun 238: 790-794, 1997.
10. Chu JL, Drappa J, Parnassa A and Elkon KB: The defect in Fas mRNA expression in MRL/lpr mice is associated with insertion of the retrotransposon, Etn. J Exp Med 178: 723-730, 1993.
11. Iwamoto S, Nishiumi E, Kajii E and Ikemoto S: An exon 28 mutation resulting in alternative splicing of the glycoprotein IIb transcript and Glanzmann's thrombasthenia. Blood 83: 1017-1023, 1994.
12. Guo WW, Moran JV, Hoffman PW, Henke RM, Butow RA and Perlman PS: The mobile group I intron 3 α of the yeast mitochondrial COXI gene encodes a 35-kDa processed protein that is an endonuclease but not a maturase. J Biol Chem 270: 15563-15570, 1995.
13. Dealtry GB, Naylor MS, Fiers W and Balkwill FR: DNA fragmentation and cytotoxicity caused by tumor necrosis factor is enhanced by interferon-γ. Eur J Immunol 17: 689-693, 1987.
14. Vanhaesebroeck B, Reed JC, De Valck D, Grooten J, Miyashita T, Tanaka S, Beyaert R, van Roy F and Fiers W: Effect of bcl-2 proto-oncogene expression on cellular sensitivity to tumor necrosis factor-mediated cytotoxicity. Oncogene 8: 1075-1081, 1993.
15. Jäättelä M, Benedict M, Tewari M, Shayman JA and Dixit VM: Bcl-x and bc12 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells. Oncogene 10: 2297-2305, 1995.
16. Cai Z, Bettaieb A, Mahdani NE, Legres LG, Stancou R, Mashah J and Chouaib S: Alteration of the sphingomyelin/ceramide pathway is associated with resistance of human breast carcinoma MCF7 cells to tumor necrosis factor α-mediated cytotoxicity. J Biol Chem 272: 6918-6926, 1997.
17. Dbaibo GS, Perry DK, Gamard CJ, Platt R, Poirier GG, Obeid LM and Hannun YA: Cytokine response modifier A (CrmA) inhibits ceramide formation in response to tumor necrosis factor (TNF)-α: CrmA and Bcl-2 target distinct components in the apoptotic pathway. J Exp Med 185: 481-490, 1997.
18. Jänickc RU, Walker PA, Lin XY and Porter AG: Specific cleavage of the retinoblastoma protein by an ICE-like protease in apoptosis. EMBO J 15: 6969-6978, 1996.
19. Duan H, Chinnaiyan AM, Hudson PL, Wing JP, He W-W and Dixit VM: ICE-LAP6. a novel mammalian homologue of the Caenorhabditis elegans cell death protein Ced3 is activated during Fas- and tumor necrosis factor-induced apoptosis. J Biol Chem 271: 1621-1625, 1996.
20. Duan H, Orth K, Chinnaiyan AM, Poirier GG, Froelich CJ, He WW and Dixit VM: ICE-LAP6, a novel member of the ICE/ Ced-3 gene family, is activated by the cytotoxic T cell protease granzyme B. J Biol Chem 271: 16720-16724, 1996.